|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #Redirect [[dal-OUTCOMES Trial]] |
| {{High density lipoprotein}}
| |
| | |
| {{CMG}}
| |
| ==Overview==
| |
| * Research studies on [[dalcetrapib]] were stopped due to lack of clinically and statistically meaningful efficacy of the drug on interim analysis.<ref name="pmid22345126">{{cite journal |author=Lüscher TF, Taddei S, Kaski JC, ''et al.'' |title=Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial |journal=[[European Heart Journal]] |volume=33 |issue=7 |pages=857–65 |year=2012 |month=April |pmid=22345126 |pmc=3345558 |doi=10.1093/eurheartj/ehs019 |url=}}</ref>
| |
| * The Dal-Outcomes study<ref name="pmid23126252">{{cite journal |author=Schwartz GG, Olsson AG, Abt M, ''et al.'' |title=Effects of dalcetrapib in patients with a recent acute coronary syndrome |journal=[[The New England Journal of Medicine]] |volume=367 |issue=22 |pages=2089–99 |year=2012 |month=November |pmid=23126252 |doi=10.1056/NEJMoa1206797 |url=}}</ref> assessed dalcetrapib at various dose ranges. This study showed a significant rise in [[HDL]] levels, but there was no significant difference between the drug and the placebo group.
| |
| ==References==
| |
| {{Reflist|2}}
| |
| | |
| {{Lipopedia}}
| |
| [[Category:Lipopedia]]
| |
| [[Category:HDL]]
| |
| [[Category:Clinical trials]]
| |